INFARTO CEREBRAL ATEROTROMBÓTICO
REFERENCIAS BIBLIOGRÁFICAS
1. Abbot RD, Reed DM, Yaro K. Risk of
stroke in male cigarette smokers. N Engl J Med 1986; 315: 717.
2. Abel GA, Sacco RL, Lin IF, et al. Race ethnic variability in etiologic fraction for
stroke risk factors: The Northern Manhattan Stroke Study. Stroke 1989; 29: 277.
3. Adams R, Victor M, Ropper A. Principios de Neurología. México. McGraw-Hill
Interamericana Ed. pp 1999; 674.
4. Adams HP, Brott TG, Crowell RM, et al. Guidelines for the management of patients with
acute ischemic stroke. A statement for the healthcare professional from a special writting
group of the Stroke Council American Heart Association. Stroke 1994; 25: 1901-14.
5. Ad Hoc Comitee of Stroke (NINDS). Classification of Cerebrovascular Diseases III.
Stroke 1990; 21: 637-76.
6. Alberts MJ. Genetics aspects of cerebrovascular disease. Stroke 1991; 22: 276-80.
7. Antiplatelet Trialist Collaboration. Collaborative overview of rabdomized trials of
antiplatelet therapy: Prevention of death, myocardial and stroke by prolonged antiplatelet
therapy in various categories of patients. BMJ 1994; 308: 81-106.
8. Atkins D, Pstay B, Koepsell T, et al. Cholesterol reduction and the risk for stroke in
man: A meta-analysis of rabdomized controled trials. Ann Intern Med 1993; 119: 736-45.
9. Axelsson K, Asplund K, Norberg A, et al. Nutritional status in patients with acute
stroke. Acta Med Scand 1988; 224: 217.
10. Badinon L, Badinon JJ, Fuster V. Pathogenesis of thrombosis. En: Fuster V, Verstraette
M ed. Thrombosis in cardiovascular disorders. Filadelfia W.B. Saunders. 1992; 6: 17-40.
11. Badinon L. Dinámica de la placa aterosclerótica y su control. Rev Neurol 1999; 29:
863.
12. Bauer RB, Sheehan S, Wechsler N, et al. Arteriographic study of sites, incidence and
treatment of arteriosclerotic cerebrovascular lesions. Neurology 1962; 12: 698-711.
13. Benafente R, Yanok Hwang LT, et al. Elevated serum cholesterol is a risk factor for
both coronary heart disease and thromboembolic stroke in hawaiian japanese men.
Implications of shared risk. Stroke 1994; 25: 814-20.
14. Berciano J. Aterosclerosis carotídea. De la genética a la prevenci6n del ictus. Rev
Neurol 1999; 29: 836-47.
15. Berger L, Hakim AM. The association of hiperglycemia with cerebral edema in stroke.
Stroke 1986; 17: 865.
16. Blawn GJ, Logaay AM, Sonict AH, et al. Stroke, statins and cholestherol: A
metaanalysis of rabdomized placebo controlled double blind trials with HMGCoA reductasas
inhibitors: Stroke 1997; 28: 946-50.
17. Brahme FJ. CT diagnosis of cerebrovascular disorders: A review. Comput Tomogr 1978; 2:
173-81.
18. Bruno A, Biller J, Adams HP, et al. Acute blood glucose level and autcome from
ischemic stroke: Trials of ORC 10172 in acute Stroke Treatment (TOAST) Investigators.
Neurology 1999; 52: 280.
19. Burchfiel CM, Curb JD, Rodriguez BL, et al. Glucose intolerance and 22 year stroke
incidence. The Honolulu Heart Program. Stroke 1994; 25. 951-57.
20. Byington RP, Jukema JW, Saloren JJ, et al. Reduction in cardiovascular events during
pravastatin therapy. Circulation 1995; 92: 2419-25.
21. Caplan LR. Cerebral ischemia and intarction in black: Clinical autopsy and
angiographic studies. A guide to management and prevention. New York. Korger pp. 1999;
7-18.
22. CAPRIE Steering Committee. A rabdomized, blinded trial of clopidogrel versus aspirin
in patients at risk of ischemic events. Lancet 1996; 348: 1329-39.
23. CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST. Randomized,
placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic
stroke. Lancet 1997; 349: 164-49.
24. Clifton GL, Robertson CS, Grossman RG, et al. The metabolic response to severe head
injury. J Neurosrg 1984; 60: 687.
25. Colditz GA, Bonita R, Stampher MJ, et al. Cigarette smoking and risk of stroke in
middle aged women. N Engl J Med. 1988; 318:937-41.
26. Crouse JB, Byington RP, Bond MA, et al. Pravastatin, lipids, and atherosclerosis in
the carotid arteries. Am J Cardiol 1995; 75: 455-59.
27. Dávalos A, Castillo J, Martinez-Vila. For the Cerebrovascular Diseases Study Group of
the Spanish Society of Neurology. Stroke 1995; 26: 2233-37.
28. Davis PH, Dambrosio JM, Schoemberg BS, et al. Risk factors for ischemic strok : A
prospective study in Rochester, Minnesota. Ann Neurol 1987; 22: 319-27.
29. De Falco FA, Sipe Visconti O, Fucci G, et al. Correlation between hyperglicemia and
cerebral infarct size in patients with stroke. A clinical and X-ray computed tomography
study in 104 patients. Schweis Arch Neurol Psychiatr 1993; 144: 233.
30. De Leciñana AN, Egido J, Gil Peralta A, et al. Infarto cerebral aterotrombótico.
Protocolos Diagnóstisco-Terapeúticos en Patología Cerebrovascular: Grupo de Estudios de
Enfermedad Cerebrovascular. S.E.N.
31. Dempsey RJ, Diana LA, Moore LD. Thickness of carotid artery atherosclerotic plaque and
ischemic risk. Neurosurg 1990; 27: 343-48.
32. Deza L, Aldave R, Barrera J. Características clínicas de los subtipos de enfermedad
vascular cerebral isquémica. Rev Neur Psiq 2000; 63: 19-36.
33. Dohlof B, Lindholm LH, Harisson L, et al. Morbity and mortality in the swedish trial
world patients with hypertension. Lancet 1991; 338: 1281-85.
34. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with
relationship to time of administration. JAMA 1996; 276: 961-66.
35. Ducker A, Diener HC, Wilhelm H. Influence of vascular risk factors for atherosclerotic
carotid artery plaque progression. Stroke 1995; 26: 2016-22.
36. Duke RJ, Bloch RF, Turpie AG, et al. Intravenous heparin for the prevention of stroke
progression in acute partial stable stroke: A randomized controlled trial. Ann Intern Med
1986; 105: 825-28.
37. Dyken M. Stroke risk factors. En: Norris JW, Hachinski. VC, eds. Prevention of stroke.
New York. Springer-Verlag 1991; 83-102.
38. Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Neurol 1998; 18:
429-39.
39. European Carotid Surgery Trialists Collaborative Group. Ramdomized trial of
endarterectomy symptomatic carotid stenosis: Final Results of the MRC European Carotid
Surgery Trial (ECST). Lancet 1998; 351: 1379-87.
40. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
41. Fine-Edelstein JS, Wolft PA, O'Larry DH, et al. Percursors of extracranial carotid
atherosclerosis. The Framingham Study. Neurology 1994; 44: 1046-50.
42. Fisher M, Pitchard JE, Mahewsw H. Atherosclerosis of the carotid arteries. Circulation
1952; 6: 457.
43. Gorelick PB, Caplan LR, Hier DB, et al. Racial differences in the distribution of
anterior circulation occlusive disease. Neurology 1984; 34: 54-59.
44. Gorelick PB, Caplan LR, Hier DB, et al. Racial differences in the distribution of
posterior circulation occlusive disease. Stroke 1985; 16: 785-90.
45. Gorelick PB, Sacco RL, Smith DB, et al. Presentation of a first stroke. A review of
guidelines and a multidisciplinary consensus statement from the National Stroke
Association. JAMA 1999; 281: 1112-20.
46. Graffagmino C, Gasecki AP, Doig GS, et al. The importance of family history in
cerebrovascular disease. Stroke 1995; 25: 1599-1604.
47. Graw AJ, Buggle F, Heindl S, et al. Recent infarction as a risk factor for
cerebrovascular ischemia. Stroke 1995; 26: 373.
48. Hacke W, Kaste M, Fieschi C, et al. ECASS Study Group. Intravenous thrombolyssis with
issue plasminogen activator for acute hemispheric stroke the European Cooperative Acute
Stroke Study (ECASS). JAMA 1995; 274: 1017-25.
49. Hacke W, Schwahss, Horn M, et al. Malignant middle cerebral artery territory
infarction: Clinical course and prognostic signs. Arch Neurol 1996; 53: 309.
50. Haley EC, Kassell NF, Torner JC. Failure of heparine to prevent progression in
progresive ischemic infarction. Stroke 1988; 19: 10-14.
51. Hawack G, Wagenknecht LE, Burke GL, et al. The atherosclerosis risk in communities
study: Cigarette smoking and progression of atherosclerosis. JAMA 1998; 279: 119-24.
52. Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode
ultrasound in population. Association with cardiovascular risk factors in the AIRC Study.
Am J Epidemiology 1991; 134: 250-56.
53. Herbert PR, Gaziano JM, Chanks, et al. Cholesterol lowering with statin drugs risk of
stroke and total mortality. JAMA 1997; 278: 313-21.
54. Heyman A, Fields WS, Keating DR. Joint Study of Extracraneal Arterial Oclussion.
Racial differences in hospitalized patients with ischemic stroke. JAMA 1972; 222: 285-89.
55. Horner J, Buoyer FG, Alberts MS, et al. Dysphagia following brainstem stroke: Clinical
correlates and outcome. Arch Neurol 1991; 48: 1170.
56. Hypertension Detection and Follow-up Program Cooperative Group: five years findings of
Hypertension Detection and Follow-up Program III: reduction in stroke incidence among
persons with high blood pressure. JAMA 1982; 247: 633-38.
57. Imparato AM, Riles JS, Gorstein F. The carotid bifurcation plaque pathologic findings
associated with cerebral ischernia. Stroke; 10: 238-45. 1979.
58. International Stroke Trial Collaborative Group. The international Stroke Trial (IST):
A randomized trial of aspirin, subcutaneus heparin, both or neither among 19,435 patients
with acute ischemic stroke. Lancet 1997; 349: 1569-81.
59. Kalva L, Yu G, Wilson K, et al. Medical complications during stroke rehabilitation.
Stroke 1995; 26: 990.
60. Kannel WB, D'Agostino RB, Wilson PV, et al. Diabetes, fibrinogen and risk of
cardiovascular disease: The Framingham experience. Am Heart J 1990; 12: 672-76.
61. Kargman DE, Tuck C, Berglun LE, et al. Elevated high density lipoprotein levels are
more important in atheroesclerotic ischemia stroke subtypes. The Northern Manhattan Stroke
Study. Ann Neurol. 1998; 44: 442-43.
62. Kiely DK, Wolf PA, Wipples A, et al. Familiar aggregations of stroke: The Framingham
Study. Stroke 1993; 24: 1366-71.
63. Kidd D, Lawson J, Nesbitt R, et al. The natural history and clinical consequences of
aspiration in acute stroke. Q J Med 1995; 88: 409.
64. Konishi M, Iso K, Konachi Y, et al. Association of sffum total Cholesterol, different
types of sftoke and stenosis disuibution of cerebral arteries: The Akia Pathological
Study. Stroke 1993; 24: 954-64.
65. Lazar HL. Enhanced presentation of acutely ischernic myocardium and improved clinical
outcomes using glucose?insulin-potassium solutions. AM J Cardiol 1997; 80: 904.
66. Marler JR, Telley B, Lu M, et al. Earlier treatment associated with better outcome in
the NINDS TPA stroke study. Stroke 1999; 30: 244 (abstr).
67. Mathew P, Teasdale G, Barman A, et al. Neurosurgical management of cerebellar
haematoma and infarct. J Neurol Neurosurg Psych 1995; 59: 287.
68. Matsumoto N, Whisnant JP, Kurland LT, et al. Natural history of stroke in Rochester,
Minnesota. An extension of previous study 1955 throught 1969. Stroke 1973; 4: 20-29.
69. McMahon S, Peto R, Cuttler J, et al. Blood presure stroke and coronary heart disease.
Part 1. prolonged differences in blood pressure. Lancet 1990; 335: 756-774.
70. Miller VT, Hart RG. Heparin anticoagulation in acute brain ischemic. Stroke 1988; 19:
403-06.
71. Mohr JP, Biller J, Hilal SK, et al. Magnetic resonance versus computed tomographic
imaging in acute stroke. Stroke 1995; 26: 807-12.
72. Mohr JP, Caplan LR, Melski JW, et al. The Harvard cooperative stroke registry: A
prospective registry. Neurology 1978; 28: 754-62.
73. Moseley M, Cohen Y, Mintorovitch J, et al. Early detection of regional cerebral
ischemia in cats: Comparison of difusion and T2-weighted MRI and spectroscopy. Mgn Reson
Med 1990; 14: 330-346.
74. Moore WB, Barentt HJ, Beebe HG, et al. Guidelines for carotid endarterectomy. A
multidisciplinary consensus statement from a ad hoc committee. Am Heart Association.
Circulation 1995; 91: 566-579.
75. MRC Working Party: Medical Research Council trial of treatment of hypertension in
older adults. Principle Results. Br Med J 1992; 304: 405-12.
76. Mulet RM, Sanchez Pérez JM, Adam A. Epidemiología descriptiva de los factores de
riesgo vascular en Bañeros. Rev Neurol 1999; 29: 593-96.
77. Muizdar JP, Wei EP, Kontos HA, et al. Mannitol causes compensatory cerebral
vasoconstriction and vasodilatation in response to blood viscocity changes. J Neurosurg
1983; 59: 822.
78. North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial
effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis.
N Engl J Med 1991; 325: 445-53.
79. Paczinski RP, He YY, Diringer MN, et al. Multiple dose mannitol reduces brain water
content in a rat model of cortical infarction. Stroke 1997; 28: 1437.
80. Pignoli P, Tremoli E, Poll A, et al. Intimal plus medial thickness of the arterial
wall. A direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-1406.
81. Powers WJ. Acute hypertension after stroke. The scientific basis for treatment
decisions. Neurology 1993; 43: 461.
82. Quzilbach N, Jones L, Warlawce et al. Fibrinogen and lipid concetrations as risk
factors for transient ischemic attacks and minor ischemic strokes, Br Med J 1991; 303:
605-09.
83. Report of the Quality Standards Subcomittee of the American Academy of Neurology.
Practice advisory thrombolytic therapy for acute ischemic stroke Summary statement.
Neurology 1996; 47: 835-39.
84. Robbins SL, Cotran RS, Kumar V. Blood vessels in pathologic bassis of disease, 31 ed.
Philadelphia. WB Saunders pp 1984; 502-506.
85. Rosens RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for
cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
86. Sacco RL, Benjamin EJ, Brodenck JP, et al. Conference Proceeding: Risk factors. Stroke
1997; 28: 1507-17.
87. Sacco RL, Kargman DE, Diong G, et al. Race?ethnicity and determinats of intracranial
atherosclerostic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995;
26: 14-20.
88. Sacco RL, Kragman DE, Zamarillo MC. Race-ethnic differences in stroke risk factors
among hospitalized patients with cerebral infarction: The Northern Manhattan Stroke.
Neurology 1995; 45: 659-63.
89. Smith GD, Shipley MJ, Marriot MG, et al. Plasma cholesterol concentrations and
mortality. JAMA 1992; 11: 24-30.
90. Sociedad Espahola de Arteriosclerosis. Arteriosclerosis, 1998; 10.
91. Sorens AG, Buonanno FS, Gonzales RG, et al. Hyperacute stroke: Evaluation with
combined multisection diffusion weighted and hemodynamically weighted echo?plantar.
Radiology 1996; 199: 391-401.
92. Stein B, Fuster V. Clinical pharmacology of platelet inhibitors. En: Fuster
Verstractte M Ed. Trombosis in cardiovascular disorders. Philadelphia. WB Saunders, 1992;
99-119.
93. Sterpetti AV, Schultz MD, Feldhaus RJ. Ultrasonographic features of carotid plaque and
the risk of subsequent neurologic deficits. Surgery 1988; 104: 652-60.
94. Stroke Units Trialists Collaboration: A systematic overview of specialist
multidisciplinsry team (stroke unit) care for stroke inpatients. Clin Invest pp 1993; 30.
95. Suallow CLM, Warlow CP. For the International Stroke. Incidence Collaboration
Comparable studies of the incidence of stroke and its pathological types. Stroke 1997; 28:
491-99.
96. Tanizaki Y, Kiyohara Y, Katol, et al. Incidence and risk factors for subtypes of
cerebral infarction in a general population. Stroke 2000; 31: 2616-22.
97. The National Institute of Neurological Disorders and Stoke rt?PA Stroke Study Group.
Tissue plasminogen activator for acute stroke. N Engl J Med 1995; 333: 1581-82.
98. The Multicenter Acute Stroke Trial Europe Study Group: Thrombolytic therapy with
streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145-50.
99. Tohma H, Karanko M. Enalaprilat controls postoperative hypertension while maintaining
cardiac function and systemic oxygenation after neurosurgery. Intensive Care Med 1995; 21:
651.
100. Toshi V, Gallo R, Lettimo M, et al. Tissue factor modulates the thrombogenicity of
human atherosclerotic plaques. Circulation 1997; 95: 594-99.
101. Wanberger J, Biscarra V, Winsberg MK, et al. Factor contributing to stroke in
patients with atherosclerotic disease of the great vessels. The rol of diabetes. Stroke
1983; 16: 709-712.
102. Warach S, Dashe J, Edelman R. clinical outcome in ischemic stroke predicted by early
diffusion-weighted and perfusion magnetic resonance imaging: A preliminary analysis. J
Cereb Blood Flow Metab 1996; 16:53-59.
103. Warach S, Li W, Ronthal M, et al. Acute cerebral ischemia: Evaluation with dinamic
contrast?enhanced MR imaging and MR angiography. Radiology 1992; 182: 41-47.
104. Whisnant JP. Effectivess versus efficacy of treatment of hypertension for stroke
prevention. Neurology 1996; 46: 301-07.
105. Whisnant JP, Homer D, Ingall TJ, et al. Duration of cigarette smoking is the
strongest predictor of severe extracranial carotid artery atherosclerosis. Stroke 1990;
21: 707-14.
106. Wijdicks EF, Scott JP. Outcome in patients with acute basilar artery occlusion
requiering mechanical ventilation. Stroke 1996; 27: 1301.
107. Wityk NJ, Llhonan D, Klaq M, et al. Race and sex differences in the distribution of
cerebral atherosclerosis. Stroke 1996; 27: 1974-80.
108. Wolf PA, Belanger AJ, D'Agostine RB. Management of risk factors: Neurol Clin 1992;
10: 177-91.
109. Wolf PA, D'Agostine RB, Belanger AJ, et al. Probability of stroke: A risk profile
from the Framingham Study. Stroke 1991; 22: 312-18.
110. Wolf PA, D'Agostine RB, Kannel W13, et al. Cigarette smoking as a risk factor for
stroke: The Framingham Study. JAMA 1988; 259: 1025.
111. Zarrans J. Neurología. Madrid. Harcout-Brace de España, 1998; 329.
Volver al Artículo
|
